Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: Evaluation of absorption, safety, and effects after intrapulmonary administration in rats

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3783-3792

  Katsumi, Hidemasa ^a   Takashima, Miki ^a   Sano, Jun Ichi ^a   Nishiyama, Kazushi ^a   Kitamura, Noriko ^a   Sakane, Toshiyasu ^a   Hibi, Toru ^b   Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b Teikoku Pharma Inc   (United States)

Author keywords

Absorption; Bioavailability; Pulmonary; Pulmonary absorption; Pulmonary delivery

Indexed keywords

ALENDRONIC ACID; LACTATE DEHYDROGENASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; GROWTH PLATE; HYPERCALCEMIA; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; MALE; NONHUMAN; OSTEOPOROSIS; PLASMA CONCENTRATION-TIME CURVE; RAT;

EID: 79960112506     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22620     Document Type: Article

References (36)

1. Schenk R, Eggli P, Fleisch H, Rosini S. 1986. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349.
2. Fleisch H. 1987. Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Orthop Relat Res 217:72-78.
3. Lambrinoudaki I, Christodoulakos G, Botsis D. 2006. Bisphosphonates. Ann N Y Acad Sci 1092:397-402.
4. Van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, Papapoulos SE. 2003. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805-811.
5. Porras AG, Holland SD, Gertz BJ. 1999. Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315-328.
6. Graham DY. 2002. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 47:1665-1678.
7. Sener G, Paskaloglu K, Kapucu C, Cetinel S, Contuk G, Ayanog lu-Dulger G. 2004. Octreotide ameliorates alendronate-induced gastric injury. Peptides 25:115-121.
8. Naniwa T, Maeda T, Mizoshita T, Hayami Y, Watanabe M, Banno S, Ito R. 2008. Alendronate-induced esophagitis: Possible pathogenic role of hypersensitivity to alendronate. Intern Med 47:2083-2085.
9. Morita T, Yamamoto A, Hashida M, Sezaki H. 1993. Effects of various absorption promoters on pulmonary absorption of drugs with different molecular weights. Biol Pharm Bull 16:259-262.
10. Owens DR, Zinman B, Bolli G. 2003. Alternative routes of insulin delivery. Diabet Med 20:886-898.
11. Katsumi H, Nakatani M, Sano J, Abe M, Kusamori K, Kurihara M, Shiota R, Takashima M, Fujita T, Sakane T, Hibi T, Yamamoto A. 2010. Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. Int J Pharm 400:124-130.
12. Lichtenberger LM, Romero JJ, Gibson GW, Blank MA. 2000. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci Sep 45:1792-1801.
13. Sadzuka Y, Nakade A, Tsuruda T, Sonobe T. 2003. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin. J Control Release 91:271-280.
14. Abuchowski A, van Es T, Palczuk NC, Davis FF. 1977. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252:3578-3581.
15. Enna SJ, Schanker LS. 1972. Absorption of saccharides and urea from the rat lung. Am J Physiol 222:409-414.
16. Wong JA, Renton KW, Crocker JF, O'Regan PA, Acott PD. 2004. Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection. Biomed Chromatogr 18:98-101.
17. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885.
18. Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547-558.
19. Xu J, Wang C, Han R, Pavlos N, Phan T, Steer JH, Bakker AJ, Joyce DA, Zheng MH. 2005. Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts. J Cell Physiol 202:554-562.
20. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. 1995. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-245.
21. Xiang A, Kanematsu M, Mitamura M, Kikkawa H, Asano S, Kinoshita M. 2006. Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice. Invest Radiol 41:704-712.
22. Kusamori K, Katsumi H, Abe M, Ueda A, Sakai R, Hayashi R, Hirai Y, Quan YS, Kamiyama F, Sakane T, Yamamoto A. 2010. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. J Bone Miner Res 25:2306-2315.
23. He L, Gao Y, Lin Y, Katsumi H, Fujita F, Yamamoto A. 2007. Improvement of pulmonary absorption of insulin and other water-soluble compounds by polyamines in rats. J Control Release 122:94-101.
24. Ezra A, Golomb G. 2000. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42:175-195.
25. Drake MT, Clarke BL, Khosla S. 2008. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045.
26. Sato M, Grasser W. 1990. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40.
27. Sener G, Sehirli O, Cetinel S, Midillioǧlu S, Gedik N, Ayanoǧlu-Dülger G. 2005. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam Clin Pharmacol 19:93-100.
28. Sener G, Goren FO, Ulusoy NB, Ersoy Y, Arbak S, Dülger GA. 2005. Protective effect of melatonin and omeprazole against alendronat-induced gastric damage. Dig Dis Sci 50:1506-1512.
29. Kanatsu K, Aihara E, Okayama M, Kato S, Takeuchi K. 2004. Mucosal irritative and healing impairment action of risedronate in rat stomachs: Comparison with alendronate. J Gastroenterol Hepatol 19:512-520.
30. Yamamoto A, Iseki T, Ochi-Sugiyama M, Okada N, Fujita F, Muranishi S. 2001. Absorption of water-soluble compounds with different molecular weights and [Asu1.7]-eel calcification from various mucosal administration sites. J Control Release 76:363-374.
31. Lindmark T, Schipper N, Lazorová L, de Boer AG, Artursson P. 1998. Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: Assessment of molecular weight dependence and demonstration of transport routes. J Drug Target. 5:215-223.
32. Gursahani H, Riggs-Sauthier J, Pfeiffer J, Lechuga-Ballesteros D, Fishburn CS. 2009. Absorption of polyethylene glycol (PEG) polymers: The effect of PEG size on permeability. J Pharm Sci 98:2847-2856.
33. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. 2006. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 12:6222-6230.
34. van beek E, Löwik C, Van der Pluijim G, Papapoulous S. 1999. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 14:722-729.
35. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. 1999. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
36. Russell RG. 2007. Bisphosphonates: Mode of action and pharmacology. Pediatrics 119:150-162.